[ < sup > 18 < /sup > F]AlF-NOTA-PCP2: a novel PET/CT tracer for enhanced PD-L1 heterogeneity imaging and comparative analysis with [ < sup > 18 < /sup > F]AlF-NOTA-WL12 in glioblastoma xenografts
CONCLUSION: [18F]AlF-NOTA-PCP2 distinguishes itself as an exceptionally sensitive PET/CT tracer, adept at non-invasively and accurately quantifying PD-L1 expression and its spatial heterogeneity in tumors, especially in GBM. Its favorable pharmacokinetic properties, safety profile, and high affinity for PD-L1 highlight its potential for enhancing the precision of cancer immunotherapy and guiding individualized treatment strategies. While promising, its clinical translation, especially in brain imaging, necessitates further validation in clinical trials.PMID:38713298 | DOI:10.1007/s00259-024-06743-5
Source: Molecular Medicine - Category: Molecular Biology Authors: Yong Wang Yang Zhang Yunhao Chen Shijie Wang Wei Liu Zhiguo Liu Man Hu Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Clinical Trials | Immunotherapy | Liver | Molecular Biology | Neurology | Study | Toxicology | Urology & Nephrology